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Abstract Methane is a greenhouse gas that oxidizes to form ground-level ozone, itself a
greenhouse gas and a health-harmful air pollutant. Reducing methane emissions will both
slow anthropogenic climate change and reduce ozone-related mortality. We estimate the
benefits of reducing methane emissions anywhere in the world for ozone-related premature
mortality globally and for eight geographic regions. Our methods are consistent with those
used by the US Government to estimate the social cost of carbon (SCC). We find that the
global short- and long-term premature mortality benefits due to reduced ozone production
from methane mitigation are (2011) $790 and $1775 per tonne methane, respectively. These
correspond to approximately 70 and 150% of the valuation of methane’s global climate
impacts using the SCC after extrapolating from carbon dioxide to methane using global
warming potential estimates. Results for monetized benefits are sensitive to a number of
factors, particularly the choice of elasticity to income growth used when calculating the value
of a statistical life. The benefits increase for emission years further in the future. Regionally,
most of the global mortality benefits accrue in Asia, but 10% accrue in the United States. This
methodology can be used to assess the benefits of methane emission reductions anywhere in
the world, including those achieved by national and multinational policies.
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1 Introduction
Methane (CH4) is a relatively short-lived and potent greenhouse gas. It also reacts in the
atmosphere to form ground-level ozone (O3) that is itself is a greenhouse gas as well as a
pollutant that is associated with adverse health effects such as impaired respiratory health and
premature mortality (US Environmental Protection Agency 2012) and damaged vegetation.
Methane is emitted by natural sources, such as wetlands, and anthropogenic sources, such as
agriculture, coal mines, municipal solid waste, oil and gas systems, and wastewater. Anthro-
pogenic activities contribute approximately 50–65%of total globalmethane emissions (IPCC
2013).
While methane has long been considered to be an important greenhouse gas to target for
climate changemitigation and is included in the basket of climate pollutants under the United
Nations Framework Convention on Climate Change (UNFCCC), it has only recently been
appreciated as a potential method to control surface ozone concentrations (West et al. 2006).
Two voluntary international efforts, the Climate and Clean Air Coalition to Reduce Short-
LivedClimate Pollutants1 (CCAC) and theGlobalMethane Initiative,2 aim to reducemethane
emissions from anthropogenic sources. Many national efforts that achieve methane emission
reductions as a primary target or as a co-benefit are also underway, including regulations like
the Oil and Natural Gas Air Pollution Standards and voluntary programs like the Natural
Gas STAR Program, the AgSTAR Program, and the Landfill Methane Outreach Program in
the US Given the many methane mitigation activities ongoing at international and national
scales, valuing both the climate and health benefits of national and international actions to
control methane emissions3 can inform policy decision-making.
Although the 12-year methane lifetime is shorter than that of many greenhouse gases (e.g.,
N2Ohas a lifetime of 110years, chloro- and perfluoro-carbons lifetimes of thousands of years,
and while CO2 doesn’t have a single lifetime, it is added to the carbon cycle for millennia), it
lives longer in the atmosphere than the other major ozone precursors (nitrogen oxides, non-
methane volatile organic compounds, and carbon monoxide), with atmospheric lifetimes on
the order of weeks or months depending on the gas (IPCC 2007). Ozone is formed as product
of the methane oxidation process, and as a result, ozone production via methane occurs on
the same decadal time scale as methane’s lifetime, long enough to be globally well-mixed in
the atmosphere [e.g., (West et al. 2006)]. Therefore, the ozone response to methane emission
reductions ismostly insensitive to the location inwhich the emissionswere reduced (ibid). The
relative uniformity of the ozone response to methane emissions allows for the quantification
of ozone benefits for a particular location per tonne of methane emission reduced anywhere
in the world. Similarly, the climate benefits of marginal reductions in methane, known as
the Social Cost of Methane (SC–CH4) have been estimated in the literature [e.g. (Marten
et al. 2014; Marten and Newbold 2012; Waldhoff et al. 2014)]. The US Government has
also calculated benefits of methane reduction using the Social Cost of Carbon4 (SCC) and
1 www.unep.org/ccac.
2 https://www.globalmethane.org/.
3 Throughout this paper we refer to the benefits of methane mitigation, though our estimates are equally valid
to estimate the damages of increases in CH4 emissions. For simplicity, we restrict our language to focus on
the benefits of mitigation.
4 The SCC, as used by the US Government, is valued in units of $/t–CO2.
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the Global Warming Potential (GWP) of methane. Using a GWP of 25 (IPCC 2007) yields
climate change benefits of (2011)$1,150/t–CH4 in 2020. The global ozone mortality benefits
of methane mitigation estimated in this paper are of similar magnitude to the monetized
climate benefits of methane mitigation. As we refer to it in this paper, the “social cost” of
methane refers only to the climate impacts, though the term could be used to refer to all the
impacts of methane including the health and agricultural impacts resulting from methane
oxidation. A cost-benefit analysis can then be done by comparing these marginal benefits—
SC–CH4 and ozone-related mortality—to the marginal cost of an emission control strategy.
Previously, studies have used global chemical transportmodeling to estimate the premature
mortality impact of ozone reductions resulting from large reductions in methane emissions
or concentration. These studies estimated that reductions of 20% in anthropogenic methane
emissions (West et al. 2006) or inmethane concentrations (Anenberg et al. 2009) would result
in about 17,000 global premature ozone-related cardiopulmonary deaths avoided (and 1.7
times that number of total avoided non-accidental deaths), or about 150–260 cardiopulmonary
deaths avoided per Mt CH4 reduced. Using similar methods but focusing on long-term ozone
concentration-mortality relationships, further implementing seven specificmethane emission
control measures around the world was also estimated to avoid 47,000 premature deaths
annually in 2030, or about 340 deaths avoided valued at approximately $1,000/tonne of
methane emission reduced (Anenberg et al. 2012; Shindell et al. 2012).
The approach taken here has been designed to produce monetized benefits of reductions
that are consistent with the methodology used for development of the US Government calcu-
lations of the SCC. In addition, this approach is novel in comparison to previous analyses that
quantify the ozone-related health impacts of CH4 reductions in that it estimates avoided respi-
ratorymortality associatedwithmitigating amarginal tonne of CH4 emissions in a given year.
The paper proceeds as follows. Section 2 presents the methodology and sources used
to estimate the indirect health benefits of CH4 mitigation. Section 3 presents the results
and discussion of multiple sensitivity tests on the short-term mortality estimates, as well as
estimated benefits of CH4 mitigation on long-termO3-related mortality. Section 4 concludes.
2 Methods
The approach taken here begins by calculating avoided respiratory mortality over several
decades associated with mitigating a marginal tonne of CH4 emissions in a given year. The
mortality reduction is then valued and discounted back to the year of emissions. The result is
a value that is well suited to regulatory analysis, enabling the estimation of the ozone-related
mortality benefits of policies that reduce CH4 emissions.
Our method makes use of the existing literature on the relationships between CH4 emis-
sions and O3 concentrations, changes in O3 concentrations and short-term mortality, future
scenarios of population and income, and the value of lives lost. The roles of each of these on
the estimates are described in turn below.
2.1 Methane Emissions and Ozone Concentrations
The analysis begins with an instantaneous pulse of 1 tonne of methane. This methane is
assumed to have a lifetime of 12years, consistent with the perturbation lifetime from the
IPCC AR4 (IPCC 2007). We consider the effect of 1 tonne of methane on short- and long-
term ozone exposure metrics (annual average ozone for short-term and the 6month average
of the 1h daily maximum ozone for long-term, consistent with the epidemiology studies
123
48 M. C. Sarofim et al.
from which ozone-mortality relationships were derived, as described below). We derive the
24-h average surface ozone response to an elevated atmospheric loading of methane from
(Fiore et al. 2008), who estimated a response of 11–15 ppt O3 as a steady state response to
1Tg reduction in annual methane emissions. Using a mean response of 13 ppt O3 and taking
into account the fact that at steady-state 1 Tg year−1 of methane is equivalent to 12Tg of
atmospheric methane loading, we calculate the ozone response in year t to a 1 Tg pulse of
methane at time zero to be
O3(t) = 13/12∗exp(−(t)/12). (1)
The April–September average of the 1-h daily maximum ozone concentration response to
an elevated atmospheric loading of methane is derived from a 3.0 to 3.6ppb change as a
steady-state response to a 139Tg reduction in annual methane emissions (Anenberg et al.
2012). We use a 70year timeframe, capturing more than 99% of the total integrated methane
loading over all time.
2.2 Ozone-Mortality Concentration-Response Relationships
We use epidemiologically-derived health impact functions to estimate changes in both pre-
mature short-term respiratory mortality related to transient changes in ozone concentration
and longer-term mortality from chronic exposure to peak ozone concentrations in response
to a pulse of methane emissions.
To estimate the mortality impacts we assume log-linear relationships between ozone con-
centration and relative risk, following (Anenberg et al. 2010). The fraction of baseline deaths
attributable to a given change in concentration (attributable fraction, AF) is:
AF = (RR − 1)/RR = 1 − exp(− βO3) (2)
where β is the slope of the log-linear relation between ozone concentration and mortality
(concentration-response factor) and O3 is the change in ozone in response to a pulse of
methane emissions. AF is multiplied by the baseline cause-specific mortality rate (y0) and
population size (pop) to estimate the change in mortality (Mort) associated with a given
change in concentration:
Mort = y0 x pop x (1 − exp(− β O3) (3)
Equation 3 is applied in each world region using the corresponding population size, baseline
mortality rate, and change in ozone concentration.
We quantify ozone-mortality impacts using two different ozone exposure metrics found
by the epidemiological literature to be associated with premature mortality: daily exposure
(“short-term”) and repeated exposure to hourly peak concentrations over the warm season
(“long-term”). For short-term exposure, we calculate β from the (Bell et al. 2004) study of
95 US urban communities, who found that a 10 ppb increase in 24-h average ozone was
associated with a 0.64% (95% posterior interval, 0.31–0.98%) increase in cardiovascular
and respiratorymortality. For long-termmortality, we calculate β from the (Jerrett et al. 2009)
study of theAmericanCancer Society study cohort of adults aged 30 and older.We use the two
pollutant model that controlled for fine particulate matter (PM2.5), which found that a 10 ppb
increase in the April-September average of the 1-h daily maximum ozone concentration was
associated with a 4% (95% confidence interval, 1.0–6.7%) increase in respiratory mortality.
Following (Anenberg et al. 2010, 2012), we apply these concentration-response relationships
found in the US globally, despite differences in exposure, susceptibility, and vulnerability
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around the world. We focus on cause-specific mortality since it is more comparable among
populations in different countries than is all-cause mortality.
2.3 Future Population Projections
To estimate the changes in mortality over time due to a reduction in CH4, it is necessary to
project population (Eq. 3, pop) and baseline mortality (Eq. 3, y0) over the coming century.
While a number of long-term projections for global population exist, e.g. (Nakicenovic
2000; United Nations 2004), in order to promote consistency and comparability with the
SCC approach, the same scenarios used by the US Government in developing and updating
the SCC (US Department of Energy 2010; US Government 2013) are used here.5 These
scenarios areBusiness asUsual (BAU) simulations from four integrated assessmentmodels—
MiniCAM, MESSAGE, MERGE, and IMAGE—that participated in the Energy Modeling
Forum 22 (EMF 22) exercise (Clarke et al. 2009). The population for each of the four models’
scenarios is aggregated to eight global regions as described in (US Department of Energy
2010). Our base estimate uses the MiniCAM scenario and the other three scenarios are used
to test the sensitivity of the results to changes in population and GDP.
We estimate the effects of long-term exposure to peak ozone concentrations only for the
population ages 30 and above, consistent with the American Cancer Society cohort used
by Jerrett et al. (2009). In order to generate this value for each of the four socioeconomic
scenarios, we first estimated the fraction of the population in this demographic using UN
country-level population projections (United Nations 2004) by age category and then aggre-
gated to our eight regions. We then applied this ratio to the total population for each of our
four socio-economic scenarios.6
2.4 Future Baseline Mortality Rates
Our methodology to estimate mortality due to ozone concentrations changes also requires
baseline rates of death due to cardiovascular and respiratory disease for the total population
and respiratory disease for the population age 30 and above.
These rates vary greatly by region and would be expected to change over time as
economies develop and mortality rates shift from infectious disease to chronic disease. This
type of information is not included in the EMF 22 scenarios used for the SCC estima-
tion. Country-level projections of total cardiovascular and pulmonary deaths through 21007
[International Futures Project (IFs) base projections (International Futures 2013)] are aggre-
gated to the eight regions corresponding to the population and GDP scenarios, weighted
by 2004 country population and cardiovascular and pulmonary death rates (Mathers et al.
2008). We apply these baseline death rates to all socio-economic scenarios. We test the
5 The SCC estimates were developed using the four models’ BAU scenarios, plus a fifth set of parameters
that are the averages of these four models’ population, GDP, and non-CO2 emissions for a GHG mitigation
policy case. Because the estimation of damages fromCH4 emissions is linearly related to population and GDP,
and does not depend on background concentrations (and therefore emissions) of GHGs, the results from this
fifth set of parameters would be a simple average of the four scenarios being used here and is therefore not
included.
6 Although scenarios with different total populations in 2100 are likely to have differing fractions of the
population in the age 30 and above category, detailed demographic projections are not available for the
individual scenarios. Thus these values should be interpreted as a sensitivity test of the total number of
individuals in the demographic category, rather than a specific scenario projection.
7 The timeframe for analysis is 70years, so emissions in the years 2040 and 2050 require baseline death rates
through 2110 and 2120, respectively. We hold death rates constant at 2100 levels through 2120.
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sensitivity of the results to baseline mortality rates using constant 2010 baseline mortality
rates.
Estimating long-term ozone mortality impacts requires baseline respiratory mortality
rates for the subset of the population ages 30 and above. We first use the Global Bur-
den of Disease (Lim et al. 2012)8 country-level, ages 30+, respiratory mortality rates for
2010, weighted and aggregated to the eight regions, then approximate annual rates through
2100 by scaling 2010 respiratory mortality with the cardiovascular and pulmonary mor-
tality rates from the IFs. We also test the sensitivity of results to constant 2010 mortality
rates.
2.5 Valuation of Changes in Mortality
In order tomonetize the reduction inmortality estimated above,we apply aValue of Statistical
Life (VSL) to the change in mortality in each future year. These values are then discounted
back to the year of emission and summed, producing a Net Present Value (NPV) of the
indirect health benefits of CH4 mitigation, measured in (2011)$/t–CH4.
Since present and future estimates of VSL for every country or region are not available,
we test the sensitivity of results to three methods of extrapolating the VSL. Each method
is anchored to the value used by the US Environmental Protection Agency for the US VSL
(US Environmental Protection Agency 2010) and then extrapolated across region and time
by assuming an elasticity (ε) of the VSL to income:
VSLx,t = VSLref,0∗(Incomex,t/Incomeref,0)ε (4)
where VSLx,t is the VSL in region x in time period t. VSLx=ref,t=0 is the VSL in a reference
region and year. In this casewe reference to theEPAVSL in theUS in 2010, adjusted to 2011$,
of $8.84 million per premature death. Income is defined in 2011$ per capita,9 and estimated
using GDP and population data from the EMF 22 scenarios (income = GDP/population).
Three elasticity sensitivities are used in this study: 0.0, 0.4, and 1.0. The elasticity of 0.4,
which is used in our base health benefit estimate, is used by (Shindell et al. 2012) . An
elasticity of 0 generates a VSL that is constant across region and time and equal to the
US 2010 VSL of (2011)$8.84 million, while an elasticity of 1.010 produces a VSL that is
proportional to income. While an elasticity of 1.0 is the largest elasticity considered in this
study, there are some studies that indicate that the income elasticity may be greater than 1 in
some cases (Hammitt and Robinson 2011).
The total annual value of reduced mortality must be discounted back to the year of emis-
sions in order to calculate the NPV. Estimates of benefits that accrue over long time horizons
(such as the SCC) are highly sensitive to the discount rate. We therefore test seven discount
rate estimates. The first four are constant discount rates of 2.5, 3.0, 5.0, and 7.0%. The first
three correspond to the discount rates used to develop the US SCC estimates and 3 and 7%
correspond to the discount rates of consumption and capital as used in US regulatory analyses
(US Office of Management and Budget 2003).
Three additional sensitivities, using a Ramsey discounting framework in which the growth
rate of income in a given region and period influence the discount rate, are also tested. The
8 Data are available at http://www.healthmetricsandevaluation.org/.
9 All values are in 2011$ unless otherwise noted. GDP data for the EMF 22 scenarios is in 2005$ and is
adjusted to 2011$ using a multiplier of 1.0608.
10 This is the value utilized by the FUND model (Anthoff and Tol 2013), which is one of the three models
used to develop the US Government’s SCC estimate.
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Ramsey discounting framework (Eq. 5) decomposes the discount rate into two parts:
rx,t = ρ+η ∗gx,t (5)
where rx,t is the discount rate for region x in time period t, η is the marginal utility of
consumption, and gx,t is the income growth rate in that region and period. The “pure rate of
time preference,” ρ, represents a strict preference for a dollar today over a dollar tomorrow
and the elasticity of the marginal utility of consumption times the GDP growth rate, η∗ gx,t ,
has the effect of increasing the discount rate for rapidly growing economies. When the
rate of growth is constant across all regions and periods, the Ramsey formula will result
in a constant value. In shorter-term, regional analyses, a constant discount rate may be a
reasonable approximation. The Ramsey formula is more appropriate when growth rates vary
greatly over time and across regions. We test the sensitivity of our results to the Ramsey
discount method with three additional discount rates. There is no clearly agreed upon value
for ρ, and very low values, like 0.1% have been used in valuing long-term climate damages,
though 1% is a more common value and estimates up to 3% have also been used. These three
estimates of ρ and η = 1 are used to estimate the three Ramsey discounting sensitivity tests.
The base estimates for both short- and long-term ozone-related mortality due to a 1 tonne
change in methane are calculated using an emission year of 2020, the MiniCAM scenario
inputs for population and GDP, average O3, central estimates of β, the IFs baseline for
y0, and a constant discount rate of 3%. We test the sensitivity of the ozone-related mortal-
ity benefits of a reduction of a marginal tonne of methane over all input parameters. These
include four additional estimates of the attributable fraction of mortality frommethane emis-
sions, including both a high and low estimate of O3 and the bounds of the 95 percentile
range estimate of β, an alternate specification of y0, GDP and population from three addi-
tional socioeconomic scenarios, six additional discount rates, two additional methods of VSL
estimation, and four other years of emission.
3 Results and Discussion
Our base estimate11 of the global avoided premature cardiovascular and pulmonary deaths due
to short-term peak ozone exposure, over a 70 year period, due to a one million tonne decrease
in methane emissions in 2020, is 239 deaths, with a monetized value of (2011)$790/t–CH4.
We estimate that a one million tonne decrease in methane emissions in 2020 will avoid 591
premature global respiratory deaths among the population aged 30+ due to long-term peak
ozone exposure, with a value of (2011)$1,775/t–CH4.12
To place these estimates in context, they can be compared to the social cost of methane.
Since 2008, US Government Regulatory Impact Analyses have used the Social Cost of
Carbon Dioxide (SCC) to estimate the climate change benefits due to a marginal (1 tonne)
reduction in carbon dioxide. Standardized values were developed in 2010 (US Department
of Energy 2010) and revised in 2013 (US Government 2013). Although the US Government
11 As described in Sect. 2, our base estimates for the value of avoided short-termmortality are discounted at a
constant 3% rate, using the MiniCAM GDP and population scenario, average O3 of 13 ppt annual average,
and β of 0.64% per 10 ppb ozone, the IFs baseline mortality projections, and a 0.4 income elasticity for VSL.
12 The base estimate of long-term mortality uses identical parameters to the short-term exposure estimate,
with the exception of O3 and β, where instead the base estimate relies on the maximum six-month average
of the 1-h daily maximum response of 24 ppt per Tg methane and the concentration-response function is 4%
per 10 ppb ozone, respectively.
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does not have a standardized SC–CH4 estimate, recent US EPA Regulations13 have included
monetized climate benefits frommethane emissions reductions.14 These estimates of the SC–
CH4 were based on the current SCC estimate, transformed using theGWP formethane. Using
the current 2020 SCC central15 value of (2011)$46 and GWP of 25 yields (2011)$1,150/t–
CH4. The SC–CH4 can also be estimated directly by the models used to estimate the SCC.
Waldhoff et al. (2014); (Marten et al. 2014) and Marten and Newbold (2012) both found
that the directly modeled relative damage of CH4 to CO2 was greater than the GWP-based
damages.16 Marten et al. (2014) use a methodology consistent with the US Government
SCC and the sensitivities tested in this paper and found that for CH4 emissions in 2020, at a
discount rate of 3%, the Social Cost of Methane was (2007)$1200 (or $1302 in 2011$). The
global ozone mortality benefits estimated in this paper are 0.7 or 1.5 times the estimate of
climate benefits using the updated SCC and GWP, and 0.6 or 1.4 times the estimate of climate
benefits from Marten et al. (2014), for the short and long-term ozone mortality estimates,
respectively.
3.1 Sensitivity Analyses
We tested the sensitivity of the results to a number of parameter assumptions and explored
the relative importance of different factors in determining the mortality benefit, as described
above. These sensitivities were all calculated relative to the base case. Sensitivity ranges were
chosen based on ranges for parameters provided within underlying studies (O3, β, Ramsey
discount rates), sensitivities used within the US Government SCC approach (discount rates
2.5, 3, and 5%, different scenarios, emission years), OMB Circular A-4 (discount rate of
7), and reasonable bounding parameters chosen by the authors (VSL elasticities and CVP
mortality rate). Therefore, while these calculations are informative, this sensitivity analysis
is not comprehensive nor are the ranges as comparable as they would be if they were all
equivalent standard deviation ranges.
Figure 1 shows the difference between the base estimate, (2011)$790/t–CH4, and each
sensitivity andTable 1 reports the estimates for each of the alternatemeasures for the specified
parameters. The estimates are very sensitive to the elasticity parameter used to extrapolate
the VSL over region and time. The use of a constant VSL (ε = 0) nearly doubles the base
estimate in 2020, while the VSL estimated as a strict ratio of per capita income (ε = 1)
produces an estimate only half of the base value.
Figure 2 shows the effect of the different VSL metrics on the CH4 mortality benefit over
time. The estimate using ε = 1 is one-half the base estimate in 2020 and increases to two-
thirds the base estimate in 2050. Similarly, an elasticity of 0 produces a mortality benefit
roughly twice as large as the base estimate in 2020, but only 1.5 times larger in 2050. That
13 Federal Register Vol 77. No. 159, 49536, 2012 and Federal Register Vol 77, No. 199, 62930, 2012.
14 Recent rules have relied on the SCC estimates developed in 2010 (central estimate of (2011)$28/t–CO2)
and two different GWP values: the Second Assessment Report GWP of 21 [for consistency with UNFCCC
guidelines (Oil and Gas)] and a GWP of 25 [(for consistency with the most recent IPCC report at the time
(Light-Duty Vehicle)]. The use of the former results in a SC–CH4 estimate of (2011)$585 and the latter in a
value of (2011)$697.
15 Due to many uncertainties in the calculation of the SCC, the US Government provides and
uses a range of SCC values. For CO2 emissions in 2020, these values range from (2011)$13
to $137. See http://www.whitehouse.gov/sites/default/files/omb/assets/inforeg/technical-update-social-cost-
of-carbon-for-regulator-impact-analysis.pdf for additional detail.
16 Differences between the GWP and explicit approaches stem mainly from the different temporal valuation
methods (combined with the fact that methane has a shorter lifetime than CO2), and the inclusion of positive
yield effects on agriculture from CO2 fertilization in some of the underlying integrated assessment models.
123
Valuing the Ozone-Related Health Benefits of Methane Emission. . . 53
Fig. 1 Differences between the short-termmortality base estimate (2011)$790/t–CH4 andmultiple parameter
sensitivities. See Table 1 for a listing of sensitivity runs for each parameter
the estimates using a constant VSL (ε = 0) are much larger than with the base method is not
particularly surprising, as the US 2010 per capita income is substantially greater than most
regions in the world at present and greater than what some regions reach even by the end of
the century in these scenarios.
The year of emission also has a large effect on the estimate, with benefits per tonne more
than doubling for methane emitted between 2010 and 2050 (Fig. 2). Within the base set of
parameters, this change is due primarily to increases in population and VSL changes due to
income growth over the time period.
Reasonable estimates of future CVP mortality rates have a comparably smaller effect on
the base case estimate in 2020: under an assumption of constant CVP mortality rates from
2010 to 2120, the benefit per tonne estimate in 2010 is only 6% lower. By 2050, however,
this assumption decreases the estimate by 30%. As shown in Table 1, the 2020 estimate is
roughly 12% lower using a constant mortality rate than under the base assumptions. Given
the extreme nature of an assumption of constant CVPmortality rates through 2120, it is likely
that other, more plausible estimations of mortality rates would have a relatively small effect
on the methane indirect health benefits.
We test a wide range of discount rates andmethods and find that the estimate of the indirect
short-term mortality impacts from a tonne of methane emitted in 2020 using a constant 2.5%
discount rate is about 1.3 times the estimate with a constant 5% discount rate. In contrast, the
SCC is very sensitive to the choice of discount rate and methodology; the SCC is nearly 5.5
times greater when discounted at 2.5 versus 5%. However, Waldhoff et al. (2014) show that
direct estimates of the SC–CH4 are also much less sensitive to discounting than the SCC,
due to methane’s comparatively short atmospheric lifetime and the resulting nearer-term
nature of the damages. The ozone-mediated mortality benefits from methane emissions are
even less sensitive to discounting. This is likely due to two reasons. First, the inertia of the
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Fig. 2 Sensitivity of short-term ozone-related mortality benefits to VSL and year of emission
climate system will cause temperature changes that last longer than concentration changes
and therefore the climate damages, but not the ozone-mediated mortality damages, will
continue to increase with future temperature changes. Second, the social cost of methane is
a function of the reference temperature as well as population and GDP. Because temperature
is increasing in the reference scenarios (even without the addition of a marginal tonne of
CH4), the climate damages from future climate changes are larger than they would be under
present temperature conditions so the climate damages decay slightly more slowly than the
mortality damages that are not dependent on temperature.
We examine four different future socio-economic scenarios, namely reference scenarios
from the EMF 22 exercise from the IMAGE, MERGE, MESSAGE, and MiniCAM models.
The use of different socioeconomic scenarios can increase the base estimate from up to 6%
in 2010 to up to 12% for emissions in 2050. The increasing sensitivity across scenarios
over time is a result of the growing differences across the models’ projections of GDP and
population as the scenarios extend into the latter part of this century.
We also examine the sensitivity of incidence results to year of emission, CVP mortality
response,O3 concentration-response factor,CVPmortality rates, and socioeconomic scenario
(Figure 3).
The concentration-response factor (β) and the year of emission reduction have the largest
effect on avoided premature mortality. The 95th percentile ranges of β bound the avoided
premature mortality between 116 and 366. Over time, a reduction of 1MMT–CH4 in a single
year increases the total avoided deaths, from 210 in 2010 to 329 in 2050.
To put these values in perspective, the recent EPA Oil and Natural Gas Sector: New
Source Performance Standards and National Emission Standards for Hazardous Air Pol-
lutants Reviews rule17 estimated that actions to reduce VOC emissions from oil and gas
production would also reduce methane emissions by 1.0 million tonnes annually, with an
17 40 CFR Parts 60 and 63.
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Fig. 3 Avoided short-term ozone-related mortality per MMT–CH4 reduction, sensitivity results
additional 0.7 million tonnes attributed to voluntary reductions. The net effect of these
reduced CH4 emissions in the year 2020 is to avoid 406 premature deaths globally from
the resulting reduction in ozone concentrations over the following 70 years. The net present
value of the avoided deaths due to reductions in 2020 CH4 emissions is $1.3 billion using
our base estimate.
3.2 Regional Estimates of Cardiovascular and Pulmonary Mortality Damages
In order to examine the distributional impacts of methane on ozone health, we present esti-
mates of avoidedmortality and benefits by region. As seen in Fig. 4, the estimates vary greatly
across regions, ranging from a low of $44/t–CH4 in Africa and the Middle East to a high of
$181/t–CH4 in East Asia under base assumptions. That the US falls somewhat in the middle
of this range may seem somewhat surprising. However, the estimates are dependent not only
on the VSL within a region, but also on the total population and the baseline cardiovascular
and pulmonary death rates. Large populations and high cardiovascular and pulmonary mor-
tality may cause the total benefits to exceed those in regions with much higher per capita
incomes. This is demonstrated in Table 2: a one million tonne decrease in emissions in 2020
avoids 12 deaths in the United States, compared to 68 avoided deaths in East Asia. The effects
of per capita income (the basis for the VSL estimates) are worth noting, however. While only
4.5% of the world’s population lives in the United States, 10.6% of the benefits are accrued
there, primarily due to differences in the estimated VSL.
As with the global values, the benefits accrued by individual regions is very sensitive to
the VSL methodology, though the magnitude, and even sign, varies across regions. When
VSL is a constant value (ε = 0), the US value is roughly 5% of the global estimate. In sharp
contrast, a VSL estimate that varies linearly with per capita income (ε = 1) increases the
fraction of benefits that accrue in the US to 25%. The effect is opposite to the effects of VSL
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Fig. 4 Percent difference in short-term ozone-related mortality results using a VSL elasticity of η = 0.4, by
region (base estimates in parentheses)
Table 2 Total avoided mortality
per 1 MMT decrease in CH4 in a
given year (base case)
Due to rounding, global totals
may not equal the sums of
regional values
Year 2010 2020 2030 2040 2050
European Union 26 29 30 32 31
United States 10 12 14 16 17
Other OECD 8 10 12 13 14
Eastern Europe 21 23 25 27 29
East Asia 56 68 81 93 102
Southeast Asia 57 64 73 83 93
Africa-Middle East 19 18 18 18 19
Latin America 13 16 18 21 24
Global 210 239 271 302 329
methodology on all other regions, where the use of a constant (ε = 0)VSL increases benefits
and the linearmethod (ε = 1) decreases benefits compared to the base assumption of ε = 0.4.
This is because the US has a relatively high VSL compared with other regions, particularly in
the near-term. A constant 2010 US VSL raises other regions’ VSLs by more than it decreases
the US value over time. When ε = 1, however, the US VSL increases linearly, rather than
exponentially at 0.4. Since other regions have lower incomes, the exponent (ε = 0.4) increases
VSL relatively more, and future increases in income in the US do not change the VSL as
much as with a ε = 1 method.
Further differences can be seen across the magnitude of response to VSL methodology
by region (Fig. 4). The use of a constant VSL across region and time has the largest effect
on the Africa-Middle East and Southeast Asia regions, increasing the benefits in each region
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nearly 175% compared to the base estimate. Generally, regions with relatively low per capita
incomes have much larger increases in benefits when ε = 0 than corresponding decrease
when ε = 1.Higher income regions (e.g. EuropeanUnion andOtherOECD) have comparable
changes between the two methods.
For further comparison, Table 2 shows the total avoided deaths for a one million tonne
decrease in methane emissions in each year. While economic growth, across regions and
over time, has a large effect on the monetized benefits, the drivers of avoided mortality are
population and baseline mortality rates, both of which vary by region and over time.
Total avoided deaths for 1 MMT–CH4 emissions reduction increases over time most
rapidly for three regions: Other OECD, East Asia, and Latin America, all seeing avoided
mortalities increase by more than 80% between 2010 and 2050. These increases are driven
primarily by rapidly increasing cardiovascular and pulmonary death rates. Similarly, the
Africa and Middle East region shows practically no change in total avoided mortality over
time. This is because the increase in population in this region is almost perfectly offset by
the decrease in cardiovascular and pulmonary death rates through mid-century.18 This region
begins the century with the lowest cardiovascular and pulmonary death rates, and though
these rates are projected to begin increasing again around 2050, by century’s end the rate is
still lower than in 2010.
3.3 Long-Term Ozone Mortality and Damages
In addition to cardiovascular and pulmonary mortality from short-term exposure to peak
ozone concentrations, changes in methane emissions can also impact respiratory mortality
from long-term exposure to average ozone concentrations. We examine the mortality effects
and damages of chronic ozone exposure due to changes in methane emissions and test the
sensitivity of the results to several parameters. While the long-term mortality results respond
similarly to the short-term estimates for most of the sensitivity tests, there are two differences
worth noting. The long-term concentration-response factor has a relatively large 95% confi-
dence interval. Because of this, the long-term respiratory mortality results are very sensitive
to this parameter, with a range of (2011)$444–$2973.
Additionally, as seen in Fig. 5, the benefits of avoided respiratorymorality due to long-term
ozone exposure increase over time at a faster rate than for the avoided cardiovascular and pul-
monary mortality due to short-term ozone exposure. The long-term benefits per tonne of CH4
mitigated increase from$1301 in2010 to$3846 in2050,while the short-termbenefits increase
from $634 to $1,428 in the same period. The primary reason for the faster increase in benefits
is that the long-termmortality impacts are based only on the sub-set of the population ages 30
and above. Globally, the affected demographic (population 30+) for the long-term impacts
is growing faster than the total population, upon which the short-term estimates are based.
The long-term mortality relationships include both acute and chronic effects of ozone
exposure, so the significantly larger long-term mortality estimates suggest that considering
only short-term mortality may exclude a substantial portion of ozone-related risk. However,
because the short-term mortality relationships include a larger population (all ages versus
adults ages 30 and older only) andmortality due to any cardiovascular and pulmonary disease
18 Although well beyond the scope of this paper to examine in detail, if other causes of mortality, such
as communicable diseases and conflict-related deaths, were to decrease significantly through the century,
the region would see a commensurate increase in cardiovascular-pulmonary mortality and total population,
thus increasing total benefits and avoided premature deaths. So although sensitivity with respect to baseline
mortality rates is tested, using constant rates over time, changes in other underlying trends in mortality causes
and rates may impact these results.
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Fig. 5 Global short-term and long-term health benefits per tonne-CH4, 2010–2050
rather than just respiratory disease, the short-term mortality estimates may include some
ozone mortality effects that are not captured in the long-term results. As the extent of the
overlap between these estimates is unknown, the short-term and long-term mortality results
should be viewed as complementary estimates, rather than additive or one as a subset of the
other.
These results can be compared to work by (Shindell et al. 2012) that shows long-term
global methane health benefit estimates in the range of $1080 ± $721/t–CH4 (in 2006$).19
There are several of differences between the Shindell et al. approach and the methods used
in this paper. The key difference is that the estimates presented in this paper follow the decay
of a pulse of methane over a period of time and reflect the value of the change in mortality
due to the resulting ozone concentration to the population in the same time period. For a
pulse of methane emitted in 2020, the ozone increment in 2020 is applied to the population
in 2020, the ozone increment in 2021 is applied to the population in 2021, and so forth, and
the changes in mortality in each region and year are valued with a region and time consistent
with estimated VSL. In contrast, Shindell et al. used a more sophisticated chemistry-climate
model to calculate the ozone changes driven by emission changes in 2030 and averaging the
ozone response in years 30–50 of the simulation. This ozone increment is then applied to the
population of 2030 in order to estimate changes in mortality. The Shindell et al. approach
would be expected to yield a result more similar to the integrated valuation of a single
year’s emissions (as in this paper) with no future changes in population, GDP, or mortality
response, and if future benefits were not discounted. In addition, Shindell et al. include PM2.5
concentration changes and health impacts resulting from CH4 emission reductions, whereas
we focus here on ozone only.
19 Or roughly (2011)$1186 ± $792, when converted using a GDP deflator of 1.098.
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3.4 Caveats and Limitations
A few of the assumptions made to develop these benefits estimates have the potential to
slightly increase the range of possible outcomes. For simplicity these estimates assume that
the ozone concentration response tomethane is homogenous.However, (Anenberg et al. 2012)
suggest accounting for the heterogeneity in ozone response to CH4 may lead to differences
in mortality estimation on the order of 15% globally, with uncertain sign. The decay rate of
methane is also not a constant, with some papers suggesting that it might change by up to
10%depending on emissions of VOCs, NOX, andmethane itself (Sarofim2012). A change in
the overall decay rate would presumably also have an effect on the rate of ozone production.
However, these effects are relatively small compared to the uncertainties involved in the
choices of VSL and discount rates considered above.
Due to lack of regional studies, we also apply concentration-response functions found in
the US globally, though differences in exposure and population susceptibility characteristics
(e.g. time spent outdoors, home ventilation rates,medical care, etc.) could cause differences in
this factor across regions.As discussed inAnenberg et al. (2010), short-termO3 epidemiology
studies in developing nations produce fairly similar results to short-term studies in North
America and Europe (Health Effects Institute International Scientific Oversight Committee
2004). Furthermore, concentration–mortality relationships do not vary significantly by sex,
age, and race (Jerrett et al. 2009; Krewski et al. 2009; Zanobetti et al. 2000), although some
sensitive populations may be at a higher risk. We base our estimates on cardiovascular and
respiratory mortality rates rather than all-cause mortality rates because this will reduce errors
due to differences in causes of deaths across regions.
These estimates also do not include the benefits of avoided morbidity. The additional
value of reduced morbidity from reductions in ozone concentrations due to lower methane
emissions would likely increase the total health benefit valuation, though precisely howmuch
is left to future work. Additional effects that would serve as a complement to both the climate
effects from the social cost of methane and the health effects from this analysis include the
effect of ozone concentrations on agricultural and forestry yields (Avnery et al. 2013) and on
the carbon uptake of natural systems (Feltzer et al. 2005).
One effect that could lead to our results being overestimates is our exclusion of par-
ticulate matter concentrations and health impacts. Reduced methane emissions may affect
atmospheric oxidant concentrations, leading to increased production of sulfate, a component
of particulate matter pollution (Anenberg et al. 2012). Increased particulate matter-related
health impacts resulting from reduced methane emissions may counteract some of the ozone-
related health benefits.
4 Conclusions and Future Directions
This paper estimates the premature mortality benefits of reducing ozone concentrations
through reductions in methane emissions. This estimate is the first one that is consistent
methodologically with the approach used in estimating the social cost of carbon values used
by the US Government for regulatory analyses. This paper also examines the sensitivity of
the estimates to several key parameters and methodologies. We estimate that a one million
tonne decrease in methane emissions in 2020 will avoid 239 premature cardiovascular and
pulmonary deaths globally due to short-term peak ozone exposure and 591 premature respi-
ratory deaths globally due to long-term peak ozone exposure. The values of these mortality
benefits are (2011)$790/t–CH4and $1,775/t–CH4, respectively. Ozone mortality benefits are
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0.7–1.5 times the estimate of climate benefits based on the US Government’s central SCC
estimate and GWP, or 0.6–0.4 times the estimate of climate benefits based on Marten et al.
(2014), with the range depending on whether the short or long-term ozone mortality esti-
mate is used. Both measures are uncertain. With the sensitivities examined here, the highest
estimate of the short-term health benefits is four times greater than the lowest. Including the
benefits estimates of long-term ozone exposure-related mortality increases the upper bound
of the range even further. The climate benefits of CH4 emissions reductions, as measured
by the SC–CH4 (calculated using the US Government’s SCC estimates and the CH4 GWP),
span a range of 10 times the lowest to the highest estimate.20
Significant differences in avoided mortality and monetized benefits exist across regions.
Differences in the number of avoided premature deaths are due to regional populations,
growth rates, and baseline cardiovascular and pulmonary death rates. While the monetized
damages are partially dependent upon the number of avoided premature deaths in a region,
the method used for the extrapolation of the VSL across regions and time has a very large
impact on the estimated monetized benefits; in some regions it has the potential to increase
monetized benefits by more than 10 times.
We find that the benefits of avoided cardiovascular and pulmonary mortality due to reduc-
tions in methane emissions are substantial and are an important benefit to include when
assessing the benefits of methane mitigation policies.
Acknowledgements The authors would like to thank Neal Fann, Amy Lamson, Bryan Hubbell, JasonWest,
and Steve Smith for reviews and comments on drafts of this paper. StephanieWaldhoff gratefully acknowledges
the U.S. Environmental Protection Agency for support of this work. Susan Anenberg performed the work on
this paper while employed by the U.S. Environmental Protection Agency. The views expressed in this paper are
those of the authors and do not reflect those of the U.S. Environmental Protection Agency, Pacific Northwest
National Laboratory, nor the U.S. Department of Energy.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 Inter-
national License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made.
References
Anenberg SC, Horowitz LW, Tong DQ, West JJ (2010) An estimate of the global burden of anthropogenic
ozone and fine particulate matter on premature human mortality using atmospheric modeling. Environ
Health Perspect 118(9):1189–1195. doi:10.1289/ehp.0901220
Anenberg SC, Schwartz J, Shindell D, Amann M, Faluvegi G, Klimont Z (2012) Global air quality and health
co-benefits of mitigating near-term climate change through methane and black carbon emission controls.
Environ Health Perspect 120(6):831. doi:10.1289/ehp.1104301
Anenberg SC,West JJ, Fiore AM, Jaffe DA, Prather MJ, Bergmann D, Zeng G (2009) Intercontinental impacts
of ozone pollution on human mortality. Environ Sci Technol 43(17):6482–6487. doi:10.1021/es900518z
Anthoff D, Tol RSJ (2013) The uncertainty about the social cost of carbon: a decomposition analysis using
fund. Clim Change 117(3):515–530. doi:10.1007/s10584-013-0706-7
Avnery S, Mauzerall DL, Fiore AM (2013) Increasing global agricultural production by reducing ozone
damages via methane emission controls and ozone-resistant cultivar selection. Glob Change Biol 19.
doi:10.1111/gcb.12118
Bell ML, McDermott A, Zeger SL, Samet JM, Dominici F (2004) Ozone and short-term mortality in 95 US
urban communities, 1987–2000. JAMA J Am Med Assoc 292(19):2372–2378
20 There are many additional factors that increase the range of SC–CH4 estimates. For instance, climate
sensitivity has a large effect on the results, the office US Government SCC estimates are based on the results
of three models, and the differences between methods used to calculate the SC–CH4 (conversion of the SCC
with GWP vs. direct estimation).
123
62 M. C. Sarofim et al.
Clarke L, Edmonds J, Krey V, Richels R, Rose S, Tavoni M (2009) International climate policy architectures:
overview of the EMF 22 international scenarios. Energy Econ 31(Supplement 2):S64–S81. doi:10.1016/
j.eneco.2009.10.013
Feltzer B, Reilly K,Melillo J, Kighlighter D, SarofimM,WangC et al (2005) Future effects of ozone on carbon
sequestration and climate change policy using a global biogeochemical model. Clim Change 73(3):28
Fiore AM, West JJ, Horowitz LW, Naik V, Schwarzkopf MD (2008) Characterizing the tropospheric ozone
response to methane emission controls and the benefits to climate and air quality. J Geophys Res Atmos
(1984–2012) 113 (D8). doi:10.1029/2007JD009162
Hammitt J, Robinson L (2011) The income elasticity of the value per statistical life: transferring estimates
between high and low income countries. J Benefit Cost Anal 2(1):1–29
Health Effects Institute International Scientific Oversight Committee (2004) Health effects of outdoor air
pollution in developing countries of Asia: a literature review. Health Effects Institute, Boston
International Futures (2013) The international futures (IFs) modeling system, Version 6.69 [Pardee FS, Center
for International Futures, Josef Korbel School of International Studies, University of Denver, Denver,
CO]
IPCC (2007) Climate change 2007: the physical science basis. Contribution of working group I to the fourth
assessment report of the intergovernmental panel on climate change [Solomon S, Qin D, Manning M,
Chen Z, Marquis M, Averyt KB, Tignor M, Miller HL (eds)]. Cambridge University Press, Cambridge,
UK and New York, USA, 996 pp
IPCC (2013) Climate change 2013: the physical science basis. Contribution of working group I to the fifth
assessment report of the intergovernmental panel on climate change [Stocker TF, Qin D, Plattner GK,
Tignor M, Allen SK, Boschung J, Nauels A, Xia Y, Bex V, Midgley PM (eds)]. Cambridge University
Press, Cambridge, UK and New York, USA, 1535 pp
Jerrett M, Burnett RT, Pope CA III, Ito K, Thurston G, Krewski D, Thun M (2009) Long-term ozone exposure
and mortality. New Engl J Med 360(11):1085–1095. doi:10.1056/NEJMoa0803894
Krewski D, JerrettM, Burnett R,MaR,Hughes E, Shi Y et al (2009) Extended follow-up and spatial analysis of
the American cancer society study linking particulate air pollution and mortality. Health Effects Institute,
Boston
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Ezzati M (2012) A comparative
risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters
in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet
380(9859):2224–2260
Marten AL, Newbold SC (2012) Estimating the social cost of non-CO2 GHG emissions: methane and nitrous
oxide. Energy Policy 51:957–972. doi:10.1016/j.enpol.2012.09.073
Mathers CD, Fat DM, Boerma J (2008) The global burden of disease: 2004 update.World Health Organization,
Geneva
Marten AL, Kopits EA, Griffiths CW, Newbold SC, Wolverton A (2014) Incremental CH4 and N2O mitiga-
tion benefits consistent with the US Government’s SC-CO2 estimates. Clim Policy:1–27. doi:10.1080/
14693062.2014.912981
Nakicenovic N (2000) Special report on emissions scenarios : a special report of working group III of the
intergovernmental panel on climate change. Intergovernmental Panel on Climate ChangeWorking Group
III, Cambridge
Sarofim M (2012) The GTP of methane: modeling analysis of temperature impacts of methane and carbon
dioxide reductions. Environmental Model Assessment. doi:10.1007/s10666-011-9287-x
Shindell D, Kuylenstierna JCI, Vignati E, van Dingenen R, Amann M, Klimont Z, Fowler D (2012) Simul-
taneously mitigating near-term climate change and improving human health and food security. Science
335(6065):183–189. doi:10.1126/science.1210026
United Nations (2004) World Population To 2300 (trans: Department of Economic and Social Affairs PD).
United Nations, New York
US Department of Energy (2010) Energy conservation program: energy conservation standards for small
electric motors, Final Rule. vol 75. Federal Register
US Environmental Protection Agency (2010) Guidelines for preparing economic analyses. http://yosemite.
epa.gov/ee/epa/eerm.nsf/vwAN/EE-0568-50.pdf
US Environmental Protection Agency (2012) Integrated science assessment for ozone and related photochem-
ical oxidants: third external review draft
USGovernment (2013) Technical support document: technical update of the social cost of carbon for regulatory
impact analysis—under executive order vol 12866. http://www.whitehouse.gov/sites/default/files/omb/
inforeg/for-agencies/Social-Cost-of-Carbon-for-RIA.pdf
US Office of Management and Budget (2003) Circular A-4: regulatory analysis. http://www.whitehouse.gov/
sites/default/files/omb/assets/regulatory_matters_pdf/a-4.pdf
123
Valuing the Ozone-Related Health Benefits of Methane Emission. . . 63
Waldhoff ST, Anthoff D, Rose SK, Tol RSJ (2014) The marginal damage costs of different greenhouse gases:
An application of FUND. Open Access Open Assess E J Econ. doi:10.5018/economics-ejournal.ja.
2014-31
West JJ, Fiore AM, Horowitz LW, Mauzerall DL (2006) Global health benefits of mitigating ozone pollu-
tion with methane emission controls. Proc Natl Acad Sci USA 103(11):3988–3993. doi:10.1073/pnas.
0600201103
Zanobetti A, Schwartz J, Gold D (2000) Are there sensitive subgroups for the effects of airborne particles?
Environ Health Perspect 108:5
123
